Literature DB >> 21475976

Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II.

Guillem Casanovas1, Dorine W Swinkels, Sandro Altamura, Klaus Schwarz, Coby M Laarakkers, Hans-Juergen Gross, Markus Wiesneth, Hermann Heimpel, Martina U Muckenthaler.   

Abstract

Congenital dyserythropoietic anaemias (CDAs) are heterogeneous, hereditary disorders hallmarked by ineffective erythropoiesis and tissue iron overload. Growth differentiation factor 15 (GDF15) was suggested to mediate iron overload in iron-loading anaemias, such as the thalassaemias and CDAI by suppressing hepcidin, the key regulator of iron absorption. Here, we show that serum GDF15 concentrations are elevated in subjects with CDAI and CDAII. Despite similar disease characteristics, CDAI patients present with significantly higher GDF15 concentrations compared to CDAII patients. Hepcidin concentrations are inappropriately low in CDAII patients considering the severe hepatic iron overload associated with this disorder. GDF15 significantly correlates with the degree of anaemia (Hb), the response of erythropoiesis (reticulocyte index) as well as with iron availability in the serum (transferrin saturation). The observation that GDF15 is elevated in CDAII patients is consistent with the proposal that GDF15 is among the erythroid factors down-regulating hepcidin and contributing to iron overload in conditions of dyserythropoiesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21475976     DOI: 10.1007/s00109-011-0751-5

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  25 in total

1.  Automated immunoturbidimetric method for measuring serum transferrin receptor.

Authors:  P Suominen; K Punnonen; A Rajamäki; R Majuri; V Hänninen; K Irjala
Journal:  Clin Chem       Date:  1999-08       Impact factor: 8.327

2.  Soluble transferrin receptor-1 levels in mice do not affect iron absorption.

Authors:  Jonathan M Flanagan; Hongfan Peng; Lei Wang; Terri Gelbart; Pauline Lee; Barbra Johnson Sasu; Ernest Beutler
Journal:  Acta Haematol       Date:  2006       Impact factor: 2.195

Review 3.  Congenital dyserythropoietic anemia type II: molecular basis and clinical aspects.

Authors:  A Iolascon; G D'Agostaro; S Perrotta; P Izzo; R Tavano; B Miraglia del Giudice
Journal:  Haematologica       Date:  1996 Nov-Dec       Impact factor: 9.941

4.  Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I.

Authors:  Hannah Tamary; Hanna Shalev; Galit Perez-Avraham; Meira Zoldan; Itai Levi; Dorine W Swinkels; Toshihiko Tanno; Jeffery L Miller
Journal:  Blood       Date:  2008-09-29       Impact factor: 22.113

5.  Liver iron concentrations and urinary hepcidin in beta-thalassemia.

Authors:  Raffaella Origa; Renzo Galanello; Tomas Ganz; Nicolina Giagu; Liliana Maccioni; Gavino Faa; Elizabeta Nemeth
Journal:  Haematologica       Date:  2007-05       Impact factor: 9.941

Review 6.  Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation.

Authors:  Hermann Heimpel; Volker Anselstetter; Ladislav Chrobak; Jonas Denecke; Beate Einsiedler; Kerstin Gallmeier; Antje Griesshammer; Thorsten Marquardt; Gritta Janka-Schaub; Martina Kron; Elisabeth Kohne
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

7.  Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency.

Authors:  Armin Finkenstedt; Paola Bianchi; Igor Theurl; Wolfgang Vogel; Derrick R Witcher; Victor J Wroblewski; Anthony T Murphy; Alberto Zanella; Heinz Zoller
Journal:  Br J Haematol       Date:  2008-12-20       Impact factor: 6.998

8.  SMAD7 controls iron metabolism as a potent inhibitor of hepcidin expression.

Authors:  Katarzyna Mleczko-Sanecka; Guillem Casanovas; Anan Ragab; Katja Breitkopf; Alexandra Müller; Michael Boutros; Steven Dooley; Matthias W Hentze; Martina U Muckenthaler
Journal:  Blood       Date:  2009-12-29       Impact factor: 22.113

9.  Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells.

Authors:  Toshihiko Tanno; Prashanth Porayette; Orapan Sripichai; Seung-Jae Noh; Colleen Byrnes; Ajoy Bhupatiraju; Y Terry Lee; Julia B Goodnough; Omid Harandi; Tomas Ganz; Robert F Paulson; Jeffery L Miller
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

10.  Hepcidin is decreased in TFR2 hemochromatosis.

Authors:  Elizabeta Nemeth; Antonella Roetto; Giovanni Garozzo; Tomas Ganz; Clara Camaschella
Journal:  Blood       Date:  2004-10-14       Impact factor: 22.113

View more
  14 in total

Review 1.  Hepcidin and iron homeostasis.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Biochim Biophys Acta       Date:  2012-01-26

Review 2.  β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.

Authors:  Yelena Ginzburg; Stefano Rivella
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

Review 3.  Regulation of the Iron Homeostatic Hormone Hepcidin.

Authors:  Veena Sangkhae; Elizabeta Nemeth
Journal:  Adv Nutr       Date:  2017-01-17       Impact factor: 8.701

Review 4.  Iron metabolism: interactions with normal and disordered erythropoiesis.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

Review 5.  A Red Carpet for Iron Metabolism.

Authors:  Martina U Muckenthaler; Stefano Rivella; Matthias W Hentze; Bruno Galy
Journal:  Cell       Date:  2017-01-26       Impact factor: 41.582

6.  The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice.

Authors:  Guillem Casanovas; Maja Vujić Spasic; Carla Casu; Stefano Rivella; Jens Strelau; Klaus Unsicker; Martina U Muckenthaler
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

7.  Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.

Authors:  Rui Cui; Robert Peter Gale; Guoqing Zhu; Zefeng Xu; Tiejun Qin; Yue Zhang; Gang Huang; Bing Li; Liwei Fang; Hongli Zhang; Lijuan Pan; Naibo Hu; Shiqiang Qu; Zhijian Xiao
Journal:  Leuk Res       Date:  2014-02-10       Impact factor: 3.156

Review 8.  Critical Issues in Diamond-Blackfan Anemia and Prospects for Novel Treatment.

Authors:  Hojun Li; Harvey F Lodish; Colin A Sieff
Journal:  Hematol Oncol Clin North Am       Date:  2018-06-05       Impact factor: 3.722

9.  Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1.

Authors:  Ilaria Ambaglio; Luca Malcovati; Elli Papaemmanuil; Coby M Laarakkers; Matteo G Della Porta; Anna Gallì; Matteo C Da Vià; Elisa Bono; Marta Ubezio; Erica Travaglino; Riccardo Albertini; Peter J Campbell; Dorine W Swinkels; Mario Cazzola
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

Review 10.  Congenital dyserythropoietic anemias: molecular insights and diagnostic approach.

Authors:  Achille Iolascon; Hermann Heimpel; Anders Wahlin; Hannah Tamary
Journal:  Blood       Date:  2013-08-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.